Amgen speaks out about bone density concerns with obesity drug
13 hours ago · AMGN. Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe. The company has tried to ...
Amgen dismisses bone density concerns related to its new …
1 day ago · AMGN. (Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from ...
Amgen Suffers Surprise Blow as New Bone Density Safety
1 day ago · Amgen lost more than 7% of its value in trading on Tuesday after reports circulated that its highly anticipated obesity candidate MariTide could have negative effects on bone mineral density, raising concerns that the investigational therapy could aggravate the risk of fractures in patients. The bone marrow density (BMD) data were first spotted ...
Amgen Stock Rebounds, Shaking Off 'Overdone' Fears Tied To Its …
1 day ago · Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.
Amgen Defends Its Investigational Monthly Weight Loss Injection …
1 day ago · William Blair notes that at lower doses of AMG 133 (140 mg and 280 mg), the reduction in bone mineral density is minimal, around 2% at most, which might not differ significantly from the placebo ...
A scrap of data on Amgen's obesity drug MariTide wipes out $12B …
2 days ago · Nov. 12, 2024. National Biotech Reporter. On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value. The data, spotted by an ...
Amgen Says No Link Between MariTide, Bone Density Loss
2 days ago · Resize. By Colin Kellaher. Amgen on Wednesday sought to allay concerns that its MariTide, investigational weight-loss shot could be linked to a loss of bone mineral density. Amgen shares fell more ...
Amgen MariTide bone mineral density loss data ‘leaked,’ says …
3 days ago · Nov. 12, 2024, 01:30 PM. Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file seems to show bone mineral density, or BMD ...
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
2 days ago · THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data. "As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern or change our ...
Amgen’s AMG-133 Phase 1 bone data ‘seems non-issue,’ says …
3 days ago · Nov. 12, 2024, 02:20 PM. Jefferies reviewed public data from the Phase 1 trial of AMG-133 showing additional measurements of bone density from obesity patients, which the firm says “could be ...
- Some results have been removed